1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Modeling anti-tumor immune responses using patient-derived melanoma organoids
- Contribution to journal › Article
- 2025
-
Mark
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
- 2024
-
Mark
Molecular patterns of resistance to immune checkpoint blockade in melanoma
- Contribution to journal › Article
-
Mark
BioMEL : a translational research biobank of melanocytic lesions and melanoma
- Contribution to journal › Article
-
Mark
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
- Contribution to journal › Scientific review
-
Mark
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
- Contribution to journal › Scientific review
- 2023
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
- Contribution to journal › Article
-
Mark
Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells
- Contribution to journal › Article
- 2022
-
Mark
DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype
- Contribution to journal › Article
